rasagiline / Generic mfg. - LARVOL DELTA

EFFECTS OF MAO-B AND COMT INHIBITORS ON SLEEP DISTURBANCES IN PARKINSON'S DISEASE: A NETWORK META-ANALYSIS (ADPD 2026) - "Inclusion criteria involved (1) patients with PD, (2) intervention/comparator consisting of MAO-B inhibitors (safinamide, rasagiline, or selegiline) and COMT inhibitors (opicapone, entacapone, or tolcapone), and (3) outcomes of improvement in parameters for subjective and objective sleep in randomized controlled trials and cohort studies. A total of 529 articles were identified during the initial search, and we ultimately conducted an NMA focusing on the final seven studies. Evidence has shown that safinamide is effective in improving objective sleep parameters in patients with PD. However, given the paucity of evidence and controlled, long-term studies, the effects of MAO-B and COMT inhibitors on sleep disturbances remain unclear. More high-quality studies will be needed and should enable clinicians to provide personalized medicine based on sleep profiles."

Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease • Sleep Disorder • COMT

EVALUATING REGIONAL VOLUMETRIC MRI BIOMARKERS AND SEGMENTATION METHODS FOR DISEASE PROGRESSION ASSESSMENT IN MULTIPLE SYSTEM ATROPHY (ADPD 2026) - P2, P3 | "Segmentation methods were further validated by assessing their scan–rescan repeatability. MRI and UMSARS data from 42 patients with MSA in 2 multicenter trials (Rasagiline for MSA, NCT00977665; PROMESA, NCT02008721) were analyzed using multiple segmentation FreeSurfer (v6.0.0 and v8.1.0; cross-sectional and longitudinal), SynthSeg, FastSurfer, and 2 in-house deep learning–based tools... This study provides the first systematic comparison of segmentation methodologies for assessing longitudinal brain volume changes in MSA. Regional volumetric MRI, when analyzed with contemporary tools, yields highly sensitive markers of disease progression, surpassing clinical scales such as UMSARS in terms of effect sizes. These findings support the use of volumetric MRI as a surrogate endpoint of disease progression in future MSA clinical trials."

Biomarker • CNS Disorders • Movement Disorders • Multiple System Atrophy

A CASE OF ACUTE DYSPHAGIA IN PROXIMAL MYOTONIC MYOPATHY WITH BENIGN TREMULOUS PARKINSONISM : DOUBLE JEOPARDY OF SWALLOWING (ADPD 2026) - "FT-CIT PET study revealed a marked bilateral presynaptic dopaminergic deficit, and rasagiline treatment was initiated. For more than 3 years, he had been keeping an independent daily activity with regular exercise (bicycling and weight training)... We report a rare case of acute dysphagia in a patient with PROMM coexisting with BTP. This case emphasizes that rapid progressive symptoms like severe swallowing dysfunction could develop in a patient with complex neuromuscular and movement disorders."

Clinical • Alopecia • Atrial Fibrillation • Cardiovascular • Cataract • CNS Disorders • Gastrointestinal Disorder • Genetic Disorders • Movement Disorders • Muscular Atrophy • Muscular Dystrophy • Myositis • Myotonic Dystrophy • Ophthalmology • Otorhinolaryngology • Parkinson's Disease

COMPARATIVE COGNITIVE EFFECTS OF MAO-B INHIBITORS IN PARKINSON'S DISEASE (ADPD 2026) - "We aimed to compare the effects of selegiline, rasagiline, and safinamide on global cognitive function and specific cognitive domains in patients with PD. Comprehensive literature searches in PubMed, Embase, and Cochrane Library identified randomized controlled trials (RCTs) assessing cognitive outcomes in PD patients treated with MAO-B inhibitors. Among MAO-B inhibitors, only rasagiline was associated with enhanced overall cognitive performance in PD, but domain-specific improvements were largely absent. These findings indicate that cognitive benefits beyond motor symptom control remain limited, and highlight the need for future long-term studies with domain-focused assessments to delineate therapeutic roles for MAO-B inhibitors in cognitive outcomes for PD patients."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Movement Disorders • Parkinson's Disease

Case Report: A possible novel adult-onset, progressive MAO-A hypofunction. (PubMed, Front Neurosci) - "The nature of the pathophysiology was then tested first by fractionated plasma catecholamine assays, performed at baseline and again using entacapone challenge to suppress catechol-O-methyltransferase function. Treatment consistent with the hypothesis consisted of rasagiline or selegiline combined with carvedilol. This treatment relieved all symptoms."

Journal • COMT

The Safety and Efficacy of Monoamine Oxidase-B Inhibitors as Add-on Therapy to Dopamine Agonists for the Treatment of Parkinson's Disease: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials (AAN 2026) - "Objective: ‎This meta-analysis aimed to examine the efficacy and safety of both irreversible and reversible monoamine oxidase B (MAO-B) inhibitors as add-on therapy in patients with Parkinson's disease.Background: Parkinson's disease (PD) is a neurodegenerative disease, treated with carbidopa/levodopa or a dopamine agonist...They can be irreversible (selegiline and rasagiline) or reversible (safinamide)... Selegiline (10mg/day) and safinamide (100mg) offer good therapeutic benefit as add-on therapy for PD. However, safinamide (100mg) has a relatively better safety profile as compared to selegiline (10mg/day). Further research should emphasize on long-term effects of these drugs through longitudinal studies focusing on patient-reported outcomes."

Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Consensus Molecules Associated with Parkinson's Disease. (PubMed, Neurol Int) - "Drugs include L-dopa (49%), carbidopa (63%), benserazide (50%), entacapone (74%), tolcapone (56%), rasagiline (76%), selegiline (46%), pargyline (4%), ropinirole (61%), pramipexole (56%), lisuride (27%), cabergoline (16%), bromocriptine (12%), and zonisamide (9%). Adjunctive therapies include droxidopa (33%), trihexyphenidyl (28%), biperiden (17%), amantadine (24%), memantine (7%), rivastigmine (13%), donepezil (6%), galantamine (4%), domperidone (6%), clonazepam (4%), tetrabenazine (16%), mazindol (13%), quetiapine (6%), and clozapine (4%). Contraindicated drugs include haloperidol (4%), sulpiride (3%), and methyldopa (6%)...Chemical inducers of PD include 6-hydroxydopamine (40%), N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 78%), tetrahydropyridine (77%), probenecid (4%), quinolinic acid (4%), 1,2,3,4-tetrahydroisoquinoline (TIQ, 16%), salsolinol (32%), rotenone (25%), and β-Methylamino-L-alanine (BMAA, 29%). Notably, our study highlights conditional essential..."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Pharmacokinetics and pharmacodynamics of anti-Parkinson drugs in geriatric patients : Key for optimization of treatment (PubMed, Z Gerontol Geriatr) - "The decarboxylase inhibitors benserazide and carbidopa possess different t1/2...Absorption and elimination of entacapone and opicapone are similar to levodopa...Rasagiline and selegiline are irreversible inhibitors of monoamine oxidase B. Therefore, in spite of their short t1/2 they are dosed once daily...Clinically established dopamine agonists activate D1/D5 dopamine motor receptors less strongly than the dopaminergic receptors of D2/D3/D4group. This is a probable reason for their numerous adverse effects particularly in older people with Parkinson's disease."

Journal • PK/PD data • CNS Disorders • Geriatric Disorders • Movement Disorders • Parkinson's Disease • COMT

Evaluation of clinically approved neuroprotective drugs as adjunct therapies in experimental cerebral malaria. (PubMed, Arch Microbiol) - "topiramate, rasagiline, vinpocetine, cilostazol, piracetam, and rivastigmine were tested for both antimalarial and anti-cerebral malaria activity. Overall, these results suggest that combining rivastigmine with α/β-arteether may represent a practical and low-cost adjunct therapy for CM. Further mechanistic and clinical studies will be essential to confirm these findings and assess long-term outcomes."

Journal • Infectious Disease • Malaria

Power and sample size calculation of two-sample projection-based testing for sparsely observed functional data. (PubMed, Stat) - "To facilitate implementation, we provide a user-friendly R package fPASS, complete with a detailed vignette to guide users through its practical application. We anticipate that this article will significantly enhance the usability of this potent statistical tool across a range of biological applications, with a particular focus on its relevance in the design of clinical trials."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Effects of MAO-B Inhibitors on Cognition in Patients with Parkinson’s Disease: A Systematic Network Meta-Analysis. (PubMed, Mov Disord Clin Pract) - "Rasagiline may provide global cognitive benefits in PD, but MAO-B inhibitors, including rasagiline, generally did not demonstrate significant effects on individual cognitive domains. These findings suggest limited cognitive impacts of MAO-B inhibitors beyond managing the motor symptoms. Further large-scale, long-term studies using domain-specific cognitive assessments are warranted to clarify their roles in cognitive performance in patients with PD."

Journal • Retrospective data • CNS Disorders • Cognitive Disorders • Dementia • Movement Disorders • Parkinson's Disease

Discovery of novel N-(prop-2-yn-1-yl)-1,2,3,4-tetrahydronaphthalen-1-amine derivatives as MAO-B inhibitors for the treatment of Parkinson's disease. (PubMed, J Enzyme Inhib Med Chem) - "Most compounds exhibited inhibitory activity and selectivity, with compounds 29 and 34 demonstrating the strongest inhibitory potency (IC50 = 0.066 ± 0.03 μM and 0.070 ± 0.002 μM, respectively) and selectivity indices (SI > 151 and 134), which were superior to the positive control rasagiline...Concurrently, they exhibited low neurotoxicity and protective effects against 6-OHDA-induced damage in SH-SY5Y neuroblastoma cells. Therefore, we propose these active compounds as potential drug candidates for further investigation."

Journal • CNS Disorders • Movement Disorders • Neuroblastoma • Oncology • Parkinson's Disease • Solid Tumor

Nocturnal Hypokinesia and Early Morning OFF in Parkinson's Disease: State-of-the-Art and Systematic Review of Treatment Availability. (PubMed, Curr Neurol Neurosci Rep) - "Pharmacologic treatments include standard and sustained-release levodopa, dopamine agonists (rotigotine, ropinirol, pramipexole, and apomorphine), MAO-B inhibitors (rasagiline, safinamide), COMT inhibitors (opicapone), and rescue therapies like inhaled or dispersible levodopa or apomorphine injection. For mild, disturbing symptoms in early PD, inhaled or dispersible levodopa or apomorphine injection are advised. In moderate to advanced stages, treatment options include long-acting dopamine agonists, MAO-B inhibitors, sustained-release levodopa, or COMT inhibitors selected based on factors such as daytime motor symptoms, and non-motor symptoms."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Fatigue and neuropsychiatric symptoms in Parkinson's disease: a narrative review. (PubMed, Front Neurol) - "Currently available therapeutic options for PD-related fatigue are limited, with rasagiline considered only "possibly useful," and most other pharmacologic and non-pharmacological strategies lacking rigorous evidence...It examines the clinical and neurobiological intersections between fatigue and neuropsychiatric symptoms in PD, highlighting key diagnostic challenges, treatment limitations, and future directions. Standardizing terminology, dissecting fatigue from overlapping neuropsychiatric symptoms, identifying reliable biomarkers, and conducting well-designed, mechanism-based clinical trials are essential next steps to redefine fatigue as a measurable and treatable symptom in PD."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Fatigue • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Effects of MAO-B and COMT inhibitors on sleep disturbances in Parkinson's disease: A network meta-analysis. (PubMed, J Mov Disord) - "However, in analyses of objective PSG data, safinamide was found to significantly increase REM sleep duration (mean difference, 5.70 [95% CI, 2.26, 9.14]) and decrease wake time after sleep onset (mean difference, -10.20 [-19.38, -1.02]) compared to rasagiline and placebo. Given the limited number and small scale of available trials, the overall evidence should be interpreted cautiously. Nonetheless, this analysis highlights the need for further high-quality trials focused on sleep outcomes to guide personalized use of MAO-B and COMT inhibitors for sleep disturbances in PD."

Journal • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease • Sleep Disorder • COMT

Interaction between rasagiline and Pueraria radix in in vitro models of parkinson's disease. (PubMed, BMC Complement Med Ther) - "These findings suggest that the RASA - PR combination offers enhanced therapeutic potential through synergistic effects, while maintaining favourable metabolic compatibility. This study establishes a scientific foundation for integrating traditional herbal medicine with conventional pharmaceuticals in PD management, potentially allowing for reduced conventional drug dosages while improving therapeutic outcomes."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Trihexyphenidyl as a Treatment for Severe Freezing of Gait in Parkinson's Disease: A Case Report (MDS Congress 2025) - "Prior treatments—including Sinemet, Rotigotine, Ropinirole, Clonazepam, Amantadine, and Rasagiline—were ineffective and caused additional symptoms like tremors and fatigue. To date, no published case studies have demonstrated significant improvement in a patient's freezing of gait (FoG) with trihexyphenidyl (Artane), except for a single case reported in 2020 (1). That study described a patient with a FoG-like gait disturbance characterized by direction-associated FoG occurring exclusively during forward walking, who experienced gait improvement with trihexyphenidyl. However, the patient's leg symptoms were more consistent with task-specific dystonia, as subsequent surface electromyography (EMG) studies revealed dystonic co-contraction in the leg during forward walking in the OFF-state, but not during backward walking or side-stepping, supporting a diagnosis of task-specific dystonia."

Case report • Clinical • CNS Disorders • Dystonia • Movement Disorders • Parkinson's Disease

Treatment Stability Across Different ADD-ON Therapies in Fluctuating Parkinson's Disease (MDS Congress 2025) - "Objective: This study investigates the efficacy and tolerability of selegiline (SL), rasagiline (RS), safinamide (SF), and opicapone (OP) in fluctuating PD patients, focusing on treatment stability and demographic influences. No single add-on therapy demonstrated superior stability, highlighting comparable efficacy across options. Sex significantly influenced therapy adjustments, with females requiring more frequent modifications. These findings underscore the importance of personalized treatment strategies in fluctuating PD management."

CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Investigation of Baseline Factors Associated with a Favorable Response to Initial MAO-B Inhibitor Treatment in Parkinson's Disease (MDS Congress 2025) - " Among 44 sporadic PD cases, 21 received MAOBIs (selegiline: 13, rasagiline: 8), 18 received levodopa, and 5 received dopamine agonists. Patients with less orthostatic hypotension and preserved postganglionic cardiac sympathetic function were more likely to benefit from MAOBIs. Their MAO-A inhibitory effect may suppress norepinephrine metabolism, enhancing motor function via dopamine activation. Therefore, PD patients with mild orthostatic hypotension and mild MIBG myocardial scintigraphy abnormalities, where endogenous norepinephrine is retained, may experience greater motor symptom improvement with MAOBIs."

CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Deep Brain Stimulation (DBS) Placement in a Patient with Parkinson's disease (PD) and Polyostotic Fibrous Dysplasia (PFD) (MDS Congress 2025) - "Multiple medications in his regimen were rasagiline, levodopa (immediate and controlled release), pramipexole and entacapone. DBS candidates with PD and a history of PFD can be evaluated, implanted and programmed."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Falls in Parkinson Disease, Videonystagmography and Fear of Falls – an Exploratory Study. (MDS Congress 2025) - "He was using levodopa, rasagiline and entacapone and was a candidate for DBS implantation. Even though both patients were independent on activities of daily living and had no significant impairment due to falls, they had high fear of falling and videonystagmography findings showing saccadic abnormalities. These findings may be related to a higher risk of falling in the near feature, which may have an impact on patients' prognosis and decision-making regarding continuous dopaminergic therapeutic strategies, but further investigation is needed to clarify if association exists."

CNS Disorders • Movement Disorders • Parkinson's Disease

Challenges in the diagnosis of the dementia spectrum: a case of behavioral variant frontotemporal dementia with idiopathic parkinson's disease (ECNP 2025) - "A 66-year-old university-educated woman with idiopathic Parkinson's disease, currently treated with rasagiline, presented with verbal expression difficulties, balance problems, disrupted sleep, and hand tremor... This case report emphasizes the importance of distinguishing Frontotemporal Dementia (FTD) from other neurodegenerative diseases.It highlights the need to consider FTD in the differential diagnosis of elderly patients exhibiting personality changes. Frontotemporal Dementia and Parkinsonism linked to chromosome 17 (FTDP-17) has also been suggested as distinct disorder. Although this patient did not have a family history, FTDP-17 can be considered."

Clinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Frontotemporal Lobar Degeneration • Movement Disorders • Parkinson's Disease • Psychiatry • Sleep Disorder • MAPT

Neuroprotective effects of chemical constituents from Nicotiana tabacum L. in Parkinson's disease. (PubMed, Nat Prod Bioprospect) - "Systematic evaluation revealed three synergistic neuroprotective mechanisms: (1) Antioxidant activity: Scopoletin (3) and isoferulic acid (6) showed significant radical scavenging capacity (ABTS assay; IC50 = 27.74, and 18.13 μM, respectively); (2) Neuronal protection: cis-11,14,17-Eicosatrienoic acid methyl ester (14) enhanced survival (93.94% vs. control) in 6-OHDA-induced PC12 cells, surpassing rasagiline (88.36% at equivalent concentrations); (3) MAO-B inhibition: five compounds displayed selective inhibition, with scopoletin (3) exhibiting highest potency (Ki = 20.7 μM). Notably, plant prostaglandins (10/11) were identified as competitive MAO-B inhibitors first time through molecular docking and 100-ns MD simulations, revealing stable binding at the FAD site (ΔG = - 10.42, and - 9.75 kcal/mol, respectively)."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Antiparkinsonian Activity of Benzenesulfonamide Derivatives, Selective MAO-B Inhibitors. (PubMed, Bull Exp Biol Med) - "Rasagiline was used as the reference drug. Only compound S13 was comparable to rasagiline in preventing the development of rigidity and hypokinesia in animals and surpassed the reference drug in correcting emotional and behavioral activity."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

The MAO-B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti-Androgen and Cytostatic Agents. (PubMed, Pharmacol Res Perspect) - "Therefore, this study evaluates the effects of the irreversible MAO-B inhibitor selegiline and rasagiline and their combinations with conventional therapies on androgen-insensitive (PC-3, DU145) and androgen-sensitive (22Rv1, LNCaP, VCaP) PAC cell lines...Combination with enzalutamide in 22Rv1, and with docetaxel in PC-3 demonstrated potentiating and additive effects, respectively. Selegiline reduced FOXA1 and GLUT1 mRNA expressions related to cancer progression and metabolism in both cell lines, increased the apoptosis-related BAX in PC-3, and decreased AR, EGFR, and SNAI2 in 22Rv1 linked to proliferation and metastasis. These findings suggest potential for selegiline repurposing in both androgen-sensitive and -insensitive PAC therapy by promoting apoptosis and inhibiting cancer growth and survival signals, respectively."

Journal • Preclinical • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • EGFR • FOXA1 • SLC2A1 • SNAI2